WESTBOROUGH, Mass., Aug. 26 /PRNewswire/ -- IBC Life Sciences announces a new Drug Discovery Series conference, Protein-Protein Interactions, to be held on November 4-6, 2002 in Newark, NJ.
lifesciencesinfo.com
Protein interactions play an integral role in developing the next generation of drug targets and therapeutics. This conference explores the latest advances and technologies for protein informatics and protein-protein interactions.
James A. Wells, Ph.D., President and Chief Scientific Officer of Sunesis Pharmaceuticals will deliver the Keynote Address: Site-Directed Drug Discovery at Signaling Interfaces.
The main conference explores:
* Utilizing High-Throughput Platforms and Cell-Based Assays to Determine Interactions
* Industry-Leading Technologies for the Discovery and Validation of Therapeutic Targets
* Novel Techniques for Rapid Identification, Mapping, and Analysis of Pathways and Interactions
* Applications in Disease Profiling, Drug Discovery, Diagnostics, and Drug Delivery
* Case studies and presentations from the following companies:
* 3-Dimensional Pharmaceuticals, Inc.
* Affinium Pharmaceuticals Inc.
* Argonne National Laboratory
* Boehringer Ingelheim Pharmaceuticals
* Bristol-Myers Squibb
* Millenium Pharmaceuticals
* MIT
* Pfizer, Inc.
* Pharmacia Corp.
* Roche Diagnostics Corporation
* The Scripps Research Institute
Plus, an IT Forums pre-conference session, "Informatics and Computational Approaches to Protein-Protein Interactions" is going to be held on Monday, November 4. IT presentations include talks by:
* James W. Fickett, Ph.D., Global Director, Bioinformatics, AstraZeneca
* Christian Reich, Ph.D., Associate Director, Computational Biology
* Giorgio Bolis, Ph.D., Assistant Director, Scientific Systems - Research
IS, Schering-Plough Research Institute
* Thomas F. Holzman, Ph.D., Project Leader, Protein Biochemistry, Global Pharmaceutical R&D, Abbott Laboratories
* Cory R. Brouwer, Ph.D., Group Leader, Bioinformatics, CuraGen Corporation
* A. Donny Strosberg, Ph.D., President and Chief Executive Officer, Hybrigenics
* Ian Welsford, Ph.D., Scientific Applications Manager, Molecular Mining Corporation ... |
